Solux to Merge with Aribio in a Transformative Deal but Existing Shareholders Face Severe Dilution
Solux Co., Ltd. has decided to merge with Aribio Co., Ltd., a private biotech firm, to pivot from LED lighting into the biotechnology sector. The surviving entity will rename to Aribio after the merger.
The merger ratio is set at 1 Solux share for 2.0610695 Aribio shares, with Solux issuing 54,359,959 new shares. This exceeds the current outstanding shares of 51,604,369, resulting in existing shareholders' ownership dropping to approximately 48.7 percent, causing severe dilution.
Aribio recorded revenue of 15.57 billion KRW and a net loss of 24.55 billion KRW in 2023. While the merger aims for technological synergy and R&D benefits, the combined entity faces short-term financial challenges due to Aribio's losses.
Appraisal rights allow shareholders to sell their shares at 10,719 KRW per Solux share, but the current market price of 4,370 KRW indicates potential high exercise. The merger contract may be terminated if appraisal requests exceed 1.5 billion KRW for Solux or 3 billion KRW for Aribio.
[AI Summary]Solux's absorption of Aribio is a strategic move into biotech but carries significant risks from massive share dilution and the target's recurring losses, posing a near-term threat to shareholder value. The merger's success hinges on stakeholder approval and future biotech performance.
KOSDAQ Filing Information
[Correction of Description] Report On Major Matters (Decision On Company Merger)